Agios Pharmaceuticals

AGIO

Market cap $2.14B

Overview Fund Activity

36.78 USD

+0.28

0.77%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

36.78

0.00

0%

1 day

0.77%

5 days

2.08%

1 month

3.96%

3 months

6.61%

6 months

15.01%

Year to date

15.52%

1 year

-18.12%

5 years

-4.29%

10 years

-59.97%

About: Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Employees: 488

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

30% more call options, than puts

Call options by funds: $11.2M | Put options by funds: $8.65M

17% more capital invested

Capital invested by funds: $1.76B [Q1] → $2.05B (+$291M) [Q2]

14% more repeat investments, than reductions

Existing positions increased: 87 | Existing positions reduced: 76

1.78% more ownership

Funds ownership: 104.73% [Q1] → 106.51% (+1.78%) [Q2]

2% less funds holding

Funds holding: 218 [Q1] → 213 (-5) [Q2]

12% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 25

33% less funds holding in top 10

Funds holding in top 10: 3 [Q1] → 2 (-1) [Q2]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$56

52% upside

Avg. target

$61

64% upside

High target

$65

77% upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Emily Bodnar	$56	Buy Reiterated	4 Sep 2025
Scotiabank Greg Harrison	$65	Sector Outperform Maintained	28 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 8 articles about AGIO published over the past 30 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO

NEW YORK , Sept. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ("Agios" or the "Company") (NASDAQ: AGIO).

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. – AGIO

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. (“Agios” or the “Company”) (NASDAQ: AGIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. – AGIO

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO

NEW YORK , Sept. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ("Agios" or the "Company") (NASDAQ: AGIO).

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO

Agios Pharmaceuticals: Why A Delayed FDA Review Could Still Be A Positive

Agios faces a pivotal FDA decision on 7 December for mitapivat's thalassemia expansion, with a good chance of approval based on strong Phase 3 data. The stock has lagged typical pre-PDUFA momentum, offering an attractive entry point for risk-tolerant investors ahead of a potential catalyst. Safety concerns exist but are likely manageable with enhanced monitoring; Agios' robust cash position provides a buffer against regulatory setbacks.

Agios Pharmaceuticals: Why A Delayed FDA Review Could Still Be A Positive

Zacks Investment Research

AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia

Agios shares tank as the FDA extends the review period for Pyrukynd in thalassemia by three months, pushing the final ruling to Dec. 7, 2025.

AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia

Agios Pharmaceuticals: New FDA Setback Likely Temporary As Issues Can Be Mitigated

Agios Pharmaceuticals, Inc. faces a three-month FDA review delay for mitapivat in thalassemia due to safety concerns, but no new efficacy or safety data was requested. Despite the setback, I remain confident in mitapivat's strong efficacy and competitive oral profile, expecting eventual FDA approval in December. Agios is financially robust with $1.3bn cash, and approval could unlock blockbuster revenues and a significant share price upside for investors.

Agios Pharmaceuticals: New FDA Setback Likely Temporary As Issues Can Be Mitigated

FDA Delays Decision On Agios Pharmaceuticals' Blood Disorder Drug For Expanded Use

On Thursday, the U.S. Food and Drug Administration (FDA) extended the Prescription Drug User Fee Act (PDUFA) goal date for Agios Pharmaceuticals, Inc.'s AGIO supplemental New Drug Application (sNDA) of Pyrukynd (mitapivat) for adult patients with non-transfusion-dependent (NTD) and transfusion-dependent (TD) alpha- or beta-thalassemia by three months to December 7, 2025.

FDA Delays Decision On Agios Pharmaceuticals' Blood Disorder Drug For Expanded Use

Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia

PDUFA goal date extended by three months from September 7, 2025, to December 7, 2025 CAMBRIDGE, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for the supplemental New Drug Application (sNDA) of PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, for the treatment of adult patients with non-transfusion-dependent (NTD) and transfusion-dependent (TD) alpha- or beta-thalassemia by three months to December 7, 2025.

Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia

Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia

Agios Pharmaceuticals today announced that the Saudi Food and Drug Authority has approved PYRUKYND® for the treatment of adult patients with thalassemia

Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia

The Motley Fool

Agios (AGIO) Q2 Revenue Jumps 45%

Agios Pharmaceuticals (AGIO -6.15%), a biotechnology company focused on therapies for rare blood disorders, released its second quarter 2025 earnings on July 31, 2025. The headline was a notable revenue beat: This quarter showcased clear progress on sales for its lead product PYRUKYND, with GAAP net product revenue of $12.5 million, yet also highlighted the company's increasing cost base as it prepares for major regulatory events and launches.

Agios (AGIO) Q2 Revenue Jumps 45%

See News Rankings

Charts implemented using Lightweight Charts™